Atopic Dermatitis: an Expanding Therapeutic Pipeline for a Complex Disease

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2021 Aug 21

PMID 34417579

Citations 152

Authors

Thomas Bieber

Affiliations

Soon will be listed here.

Abstract

Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates. In addition to regulatory approval for the IL-4Ra inhibitor dupilumab, the anti-IL-13 inhibitor tralokinumab and the JAK1/2 inhibitor baricitinib in Europe, there are now more than 70 new compounds in development. This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease.

Citing Articles

Novel drug delivery systems in topical treatment of atopic dermatitis.

Dabhadkar M, Kulkarni M Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40080153 DOI: 10.1007/s00210-025-04002-4.

Review on role of honey in disease prevention and treatment through modulation of biological activities.

Rahmani A, Babiker A Open Life Sci. 2025; 20(1):20251069.

PMID: 40059876 PMC: 11889511. DOI: 10.1515/biol-2025-1069.

Economic burden of atopic dermatitis in Portugal: a cross-sectional study.

Cunha A, Vitorino G, Silva J, Coelho P Sci Rep. 2025; 15(1):7717.

PMID: 40044763 PMC: 11882976. DOI: 10.1038/s41598-025-91896-y.

Seasonal Changes in the Severity of Atopic Dermatitis by Birth Season: A Pilot Prospective Cohort Study.

Zhang Y, Li H, Zhang Y, Tan C, Xie B Acta Derm Venereol. 2025; 105:adv41987.

PMID: 40026107 PMC: 11894290. DOI: 10.2340/actadv.v105.41987.

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.

Guttman-Yassky E, Simpson E, Bissonnette R, Eichenfield L, Kabashima K, Luna P Immunotherapy. 2025; 17(2):83-94.

PMID: 40012373 PMC: 11901500. DOI: 10.1080/1750743X.2025.2464528.

References

Stander S, Luger T . NK-1 Antagonists and Itch. Handb Exp Pharmacol. 2015; 226:237-55. DOI: 10.1007/978-3-662-44605-8_14. View

Berdyshev E, Goleva E, Bronova I, Dyjack N, Rios C, Jung J . Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight. 2018; 3(4). PMC: 5916244. DOI: 10.1172/jci.insight.98006. View

Inoue K, Tsuda M . Nociceptive signaling mediated by P2X3, P2X4 and P2X7 receptors. Biochem Pharmacol. 2020; 187:114309. DOI: 10.1016/j.bcp.2020.114309. View

Dicpinigaitis P, McGarvey L, Canning B . P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough. Lung. 2020; 198(4):609-616. DOI: 10.1007/s00408-020-00377-8. View

Yew Y, Thyssen J, Silverberg J . A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2018; 80(2):390-401. DOI: 10.1016/j.jaad.2018.09.035. View

Somma T, Cinci L, Formicola G, Pini A, Thurmond R, Ennis M . A selective antagonist of histamine H₄ receptors prevents antigen-induced airway inflammation and bronchoconstriction in guinea pigs: involvement of lipocortin-1. Br J Pharmacol. 2013; 170(1):200-13. PMC: 3764861. DOI: 10.1111/bph.12264. View

Myles I, Castillo C, Barbian K, Kanakabandi K, Virtaneva K, Fitzmeyer E . Therapeutic responses to in atopic dermatitis may involve lipid-mediated TNF-related epithelial repair. Sci Transl Med. 2020; 12(560). PMC: 8571514. DOI: 10.1126/scitranslmed.aaz8631. View

Birdi G, Cooke R, Knibb R . Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020; 59(4):e75-e91. DOI: 10.1111/ijd.14763. View

Nakagawa H, Nemoto O, Igarashi A, Saeki H, Murata R, Kaino H . Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2019; 47(2):114-120. PMC: 7028108. DOI: 10.1111/1346-8138.15173. View

10.

Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W . Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2014; 64(1):41-51. PMC: 4286029. DOI: 10.1007/s00011-014-0782-9. View

11.

Cotter D, Schairer D, Eichenfield L . Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2017; 78(3 Suppl 1):S53-S62. DOI: 10.1016/j.jaad.2017.12.019. View

12.

Karuppuchamy T, Behrens E, Gonzalez-Cabrera P, Sarkisyan G, Gima L, Boyer J . Sphingosine-1-phosphate receptor-1 (S1P) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 2016; 10(1):162-171. PMC: 5053832. DOI: 10.1038/mi.2016.35. View

13.

Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, Stark H, Werfel T . The histamine H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol. 2009; 123(3):619-25. DOI: 10.1016/j.jaci.2008.12.1110. View

14.

Jarvikallio A, Harvima I, Naukkarinen A . Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res. 2003; 295(1):2-7. DOI: 10.1007/s00403-002-0378-z. View

15.

Wu J, Guttman-Yassky E . Efficacy of biologics in atopic dermatitis. Expert Opin Biol Ther. 2020; 20(5):525-538. DOI: 10.1080/14712598.2020.1722998. View

16.

Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y . Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2017; 73(1):29-36. DOI: 10.1111/all.13239. View

17.

Han H, Roan F, Ziegler S . The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017; 278(1):116-130. PMC: 5492959. DOI: 10.1111/imr.12546. View

18.

Jurgens M, Wollenberg A, Hanau D, de la Salle H, Bieber T . Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc epsilon RI. J Immunol. 1995; 155(11):5184-9. View

19.

Howell M, Kim B, Gao P, Grant A, Boguniewicz M, DeBenedetto A . Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007; 120(1):150-5. PMC: 2669594. DOI: 10.1016/j.jaci.2007.04.031. View

20.

Igawa S, Ohzono A, Pham P, Wang Z, Nakatsuji T, Dokoshi T . Sphingosine 1-Phosphate Receptor 2 Is Central to Maintaining Epidermal Barrier Homeostasis. J Invest Dermatol. 2020; 141(5):1188-1197.e5. PMC: 9801230. DOI: 10.1016/j.jid.2020.09.026. View